With the aim of targeting prostate cancer (PCa), a PtIV prodrug (for CDDP) has been encapsulated into aptamer (Apt)-targeted poly

(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) nanoparticles (NPs) forming a Pt-PLGA-b-PEG-Apt-NP conjugate (40) engineered to target the prostate-specific membrane antigen (PSMA). These nanoparticles demonstrated enhanced in vivo pharmacokinetics (PK), biodistribution, tolerability and efficacy. The maximum tolerated dose (MTD) for Pt-PLGA-b-PEG-NP was 40 mg/kg while that of CDDP and the prodrug alone was 20 mg/kg. The Pt in 40 remained in systemic circulation one hour post-administration [ 41••], longer than for cisplatin itself. Since the androgen receptor (AR) is upregulated in breast, IWR-1 manufacturer ovarian and prostate tumour cells, Huxley et al. have designed multiple androgenic steroidal ligands with various nitrogen-containing heterocyclic rings conjugated to either cis-platin or trans-platin (41 and 42, Figure 3d) as platinum drug delivery vectors. These [PtII(NH3)2Cl(steroid)] conjugates were 2–12-fold more cytotoxic than the non-steroidal complexes, but with a similar activity range as CDDP. Interestingly, the cis-complex conjugates displayed two to threefold higher activity than their trans analogues. Conjugation to lipophilic testosterone appears to help the cationic complexes through the cell membrane [ 42]. Many proliferating cells have a high

demand for cobalamin Afatinib datasheet (Cbl, coenzyme vitamin B12) making it an attractive carrier. Enzymatic reduction of complexes of the type B12-CN-PtII (Figure 3g) releases PtII diammine complexes. Complex 43 was the most active but still with an IC50 ca. 27-fold

higher than free CDDP; conjugates 44 and 45 were ca. 180-fold less active than free cisplatin towards A2780 ovarian and MCF-7 breast cancer cell lines. The reduced cytotoxicity was attributed to a low receptor-mediated response [43]. Nowotnik et al. have reviewed the nano-polymer, ProLindac™ (46), consisting of the active Pt(R,R-dach)2+ fragment of oxaliplatin bound to hydroxypropylmethacryl-amide (HMPA). Release of the active platinum pharamacophore Montelukast Sodium was ca. seven-times greater at pH 5.4 in comparison to pH 7.4 after 24 hours. The superior activity of ProLindac™ over oxaliplatin was shown in both human and mouse xenograft models, while the cytotoxicity profile of 46 was similar to oxaliplatin [ 2•• and 44]. Release of nitric oxide (NO) from prodrugs is usually activated by glutathione reductase in tumour cells resulting in growth inhibition of cancerous tissues. Duan et al. have synthesised both hydrophilic poly(acrylic)-cis-[Pt(NH3)2(carboxylate)2] (47 and 48) and hydrophobic NO-donating (49) prodrugs ( Figure 3h) combining NO prodrug therapy with Pt based-therapy. The extended life-times of both prodrugs suggest potential future use in combination therapy.